Elite Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) to the FDA for a generic anticoagulant drug. The branded version of this drug class generated $26 billion in sales over the past year, but no generic alternatives currently exist due to unexpired patents and exclusivities. Approval and market entry depend on FDA review and resolving patent issues. This move could open a significant market opportunity for Elite if successful.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Citigroup downgraded Apollo Global Management's stock from Buy to Reduce due to concerns over a potential economic slowdown and a sharp drop in U.S. private credit lending. Apollo's shares are trading well below their 52-week high, reflecting caution...
Conagra Brands reported its Q2 earnings with an EPS of $0.47, slightly beating estimates but down from last year. Revenue missed expectations at $2.88 billion, and the company announced a loss and a significant dividend cut as part of a new conservat...
